Back to overview

Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study.

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author May Margaret T, Vehreschild Jorg-Janne, Trickey Adam, Obel Niels, Reiss Peter, Bonnet Fabrice, Mary-Krause Murielle, Samji Hasina, Cavassini Matthias, Gill Michael John, Shepherd Leah C, Crane Heidi M, d'Arminio Monforte Antonella, Burkholder Greer A, Johnson Margaret M, Sobrino-Vegas Paz, Domingo Pere, Zangerle Robert, Justice Amy C, Sterling Timothy R, Miró José M, Sterne Jonathan A C, Antiretroviral Therapy Cohort Collaboration (ART-CC),
Project Swiss HIV Cohort Study (SHCS)
Show all

Original article (peer-reviewed)

Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume (Issue) 62(12)
Page(s) 1571 - 7
Title of proceedings Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
DOI 10.1093/cid/ciw183

Open Access

Type of Open Access Publisher (Gold Open Access)


CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterized. We estimated mortality rates (MRs) by time since start of ART (<0.5, 0.5-0.9, 1-2.9, 3-4.9, 5-9.9, and ≥10 years) among patients from 18 European and North American cohorts who started ART during 1996-2001. Piecewise exponential models stratified by cohort were used to estimate crude and adjusted (for sex, age, transmission risk, period of starting ART [1996-1997, 1998-1999, 2000-2001], and AIDS and human immunodeficiency virus type 1 RNA at baseline) mortality rate ratios (MRRs) by CD4 count at start of ART (0-49, 50-99, 100-199, 200-349, 350-499, ≥500 cells/µL) overall and separately according to time since start of ART. A total of 6344 of 37 496 patients died during 359 219 years of follow-up. The MR per 1000 person-years was 32.8 (95% confidence interval [CI], 30.2-35.5) during the first 6 months, declining to 16.0 (95% CI, 15.4-16.8) during 5-9.9 years and 14.2 (95% CI, 13.3-15.1) after 10 years' duration of ART. During the first year of ART, there was a strong inverse association of CD4 count at start of ART with mortality. This diminished over the next 4 years. The adjusted MRR per CD4 group was 0.97 (95% CI, .94-1.00; P = .054) and 1.02 (95% CI, .98-1.07; P = .32) among patients followed for 5-9.9 and ≥10 years, respectively. After surviving 5 years of ART, the mortality of patients who started ART with low baseline CD4 count converged with mortality of patients with intermediate and high baseline CD4 counts.